Kornimate/medical-research-clean huggingface dataset:
kefir cholesterol lowering pilot study

Conditions: Hypercholesterolemia

Summary: high cholesterol (a type of fat in humans blood) may be one factor that can lead to heart disease. if people have higher cholesterol, it is possible that kefir (a food similar to yogurt) may help to control blood cholesterol levels.

new research shows that kefir (which contains bacteria also known as microbes), similar to yogurt, may improve health by lowering cholesterol levels. much of this research however, focuses on traditional types of kefir, which differ significantly from commercially prepared kefir with regards to the types of microbes in each kefir. additionally, there is a lack of research looking at how commercial kefir compares to traditional kefir in its ability to improve health. this has led to the consumer being confused about the health benefits they believe they are receiving, such as reduced weight gain, and improved cholesterol levels, when they purchase and consume commercial kefir. the researchers have produced a commercially usable kefir that has the health benefits of traditional grain fermented kefir. this was accomplished with only a small subset of microbes present in the traditional kefir, leading to a much easier product to commercialize and produce. thus, this study aims to look at whether kefir, produced in the researchers laboratory and commercially available kefir, given to males for in two separate months, results in any cholesterol lowering effects. successful completion of this project could potentially result in the development of a new commercial kefir with health benefits that are supported by scientific research and testing. in addition, if positive results are seen, a larger study will be carried out to ensure that results of the current study are consistent for the canadian population.

Eligibility criteria:
inclusion criteria: 1. males, aged 18-65y 2. moderately hypercholesterolemic adults: ldl-c between 3.2 and 4.9 mm, but otherwise healthy 3. no history of cvd, type 2 diabetes, monogenic dyslipidemia or use of medications for hyperlipidemia (including statins). 4. no dairy allergy exclusion criteria: -

Keywords: high cholesterol, kefir
sleep apnea in look ahead participants - ancillary to look ahead

Conditions: Sleep Apnea Syndromes; Diabetes Mellitus, Non-insulin Dependent; Obesity; Diabetes Mellitus

Summary: to assess the effects of weight loss on sleep disordered breathing in obese, type 2 diabetics with obstructive sleep apnea.

background: weight loss is a frequently recommended treatment for obese patients with obstructive sleep apnea (osa). the empirical support for this recommendation is lacking. based on descriptive studies, weight loss appears to improve but not abolish sleep disordered breathing. moreover, the degree of improvement in osa is quite variable and not directly proportional to weight loss. the lack of randomized trials, the study of predominantly male samples, and the absence of follow-up evaluations leave physicians and patients unsure about the utility of weight loss treatment in obese osa patients. the study is ancillary to the look ahead clinical trial which is sponsored primarily by the national institute of diabetes and digestive and kidney diseases and secondarily by the national heart, lung, and blood institute, the national institute of nursing research, the office of research on women's health, the national center on minority health and health disparities, and the centers for disease control and prevention. the look ahead study is a multicenter, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss in overweight diabetics. design narrative: the study will assess the effects of weight loss on sleep disordered breathing in 120 obese, type 2 diabetics with obstructive sleep apnea (respiratory disturbance index \[rdi\] greater than or equal to 15) who are randomly assigned to either weight loss (n=60) or usual care (n=60) treatments within the context of the look ahead study. home polysomnography studies will be performed before treatment and at one and two years. among the 60 weight loss subjects, the investigators will assess the relative importance of changes in neck and abdominal fat in explaining the variability of changes in sleep disordered breathing after weight loss. finally, they will examine the relationship between changes in sleep-disordered breathing and changes in blood pressure after weight loss in the 60 weight loss participants. specifically, this research will: 1) determine the efficacy of a weight loss program in reducing sleep disordered breathing in obese type 2 diabetics; 2) identify sources of variability in sleep disordered breathing associated with weight loss; and 3) examine the role of sleep disordered breathing in mediating changes in blood pressure associated with weight loss. the results of this study will provide an empirical basis for making recommendations about the effectiveness of weight loss in type 2 diabetics with osa.

Eligibility criteria:
an estimated 176 obese, diabetic subjects with obstructive sleep apnea, 50% women and 40% minorities.
vascular closure for cardiac ablation registry (vaccar)

Conditions: Atrial Fibrillation

Summary: the objective of this registry is to find out if there is a difference in patient satisfaction and rate of vascular and bleeding complications with use of perclose proglide system or f08s for venous closure post atrial fibrillation and atrial flutter procedures in comparison to manual compression.

vascular closure devices (vcd) have been used to achieve hemostasis of arterial access sites following cardiac catheterization procedures. there is extensive literature available supporting the use of these devices for arterial access site closure, showing reduced time to hemostasis, earlier ambulation and reduced length of hospital stay in comparison to manual compression which is the traditional approach to achieve access site hemostasis. in contrast, there is not significant evidence supporting the use of these devices for closure of femoral venous access site, partly due to limited use of vcd in cardiac electrophysiology procedures, such as catheter ablation for atrial fibrillation and atrial flutter. another alternative to manual compression, the figure of 8 stitch has also been used to achieve vascular closure follow catheter ablation of atrial fibrillation and atrial flutter, however it has not been studied formally. the aim of this registry is to better understand the 'real-world' utilization of vcd or figure of 8 stitch(f08s) in cardiac ablation procedures and to understand any potential difference between vcd or f08s and manual compression. the outcomes of interest are vascular access site complication rate, time to ambulation and patient perception of pain and overall satisfaction, which is assessed via a survey. the hypothesis of this registry is that there will be an increased patient satisfaction and decreased rate of vascular and bleeding complications with use of either perclose proglide system or figure of 8 stitch for venous closure post atrial fibrillation ablation and atrial flutter ablation procedures in comparison to standard manual compression. the design will be a prospective observational registry collecting data on patients who underwent catheter ablation for atrial fibrillation and atrial flutter, including administration of a patient survey.

Eligibility criteria:
inclusion criteria: * patients undergoing a catheter ablation procedure (radiofrequency ablation or cryoablation) to treat symptomatic paroxysmal atrial fibrillation or atrial flutter * patients willing to participate in a short written survey exclusion criteria: * patients undergoing ablation for an arrhythmia other than atrial fibrillation/atrial flutter or who are not candidates for an ablation procedure for treatment of atrial fibrillation/atrial flutter * patients who are not able to read or understand the english language * patients who had recent access site complications within the same hospitalization * patients who have baseline thrombocytopenia (platelet count less than 80) or known coagulopathy (inr \> 1.5)

Keywords: atrial fibrillation vascular closure
parotid-gland stem-cell sparing intensity-modulated radiotherapy

Conditions: Head and Neck Cancer

Summary: rationale: radiation-induced parotid gland dysfunction, often leading to xerostomia is the most-frequently occurring side-effect with a major impact on patient-reported quality of life after radiotherapy for head and neck cancer (hnc). therefore, treatments for hnc are currently optimized to minimize the mean dose to the parotid glands. though this resulted in a significant reduction of toxicity, 30%-40% of the patients still develop sustained parotid gland dysfunction and xerostomia. however, in animal studies the investigators found that the dose to the sub-volume of the gland containing the parotid gland stem cells is a better predictor for dysfunction than the mean dose to the whole gland. subsequently, this finding was confirmed in a retrospective analysis in patients. therefore, a reduction of dose specifically in this sub-volume of the parotid glands of patients is expected to further reduce the risk of parotid gland dysfunction and xerostomia. objective: to test the hypothesis that parotid gland stem cell sparing intensity modulated radiotherapy in hnc patients reduces the risk of parotid gland dysfunction and xerostomia as compared to conventional parotid gland sparing intensity modulated radiotherapy. study design: double-blind prospective randomized trial (51 patients per arm). study population: patients treated for tumours in the head-and-neck region with curative radiotherapy, with or without the addition of chemotherapy or cetuximab. intervention: patients randomized into the experimental arm will receive a treatment in which the radiation dose to the parotid gland is re-distributed to minimize dose to the sub-volume containing the stem cells, while keeping the same mean dose to the parotid gland as a whole. main study parameters/endpoints: primary endpoint is parotid gland salivary secretion. secondary endpoints are patient- and physician-rated xerostomia.


Eligibility criteria:
inclusion criteria: * squamous cell carcinoma originating from the mucosa of the head and neck area or nasopharyngeal carcinoma originating from the nasopharynx; * the radiotherapy includes prophylactic or therapeutic irradiation of both sides of the neck (at least level ii to iv); * age ≥ 18 years; * who performance 0-2; * to reduce the uncertainty in the assessment of relative flow after treatment, pre-treatment parotid gland saliva production stimulated with 5% citric acid should exceed \>0.1 ml/min exclusion criteria: * postoperative radiotherapy; * previous radiotherapy of the head and neck region (re-irradiation); * unilateral radiotherapy; * primary salivary gland tumours

Keywords: head and neck cancer radiotherapy imrt stem cell parotid gland
cardiopulmonary exercise test assessing multiple biomarkers in type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: collection of venous blood samples in male t1d patients to evaluate the behavior of different biomarkers (beta-hydroxybutyrate, lactate, glucose) during and after morning aerobic (60% of vo2 max) and symptom limited maximal exercise test.

compare values and trends of different biomarkers (glucose, lactate and beta-hydroxybutyrate) before, during and after morning aerobic and symptom limited maximal exercise (cycling) to predict glycemic fluctuations (hypo- and hyperglycemic events) during and after exercise in order to create treatment algorithms to prevent these events. endpoint: • evaluate values and trends of glucose, lactate and beta-hydroxybutyrate before, during and after morning exercise in venous blood.

Eligibility criteria:
inclusion criteria: * male adults (18-40 years old) with t1d, diagnosed since \> 1 year * using a cgm (dexcom g5) or willing to wear a cgm (dexcom g5) for the duration of the study. the cgm must be applied \>48h before the exercise test * participants are on intensified insulin therapy (mdi) or insulin pump therapy (csii) * 6% ≤ hba1c ≤ 8% * having a self-reported moderate activity level on the ipaq (internationally physical activity questionnaire). * c-peptide \<0.2 nmol/l * the physical activity coefficient has not changed in the 2 months prior to the first exercise test. * 20kg/m2 \< bmi \< 25kg/m2 exclusion criteria: * recently diagnosed t1d (\< 12mo) * participants not on mdi or csii * musculoskeletal disorder that affects cycling or is a contra-indication for vigorous physical activity * cardiorespiratory disease or ecg abnormality that is a contra-indication for vigorous physical activity * having an acute illness (e.g. influenza) that interferes with glucose metabolism * having a metabolic disorder (different from diabetes) or takes drugs known to have significant interference with glucose metabolism, such as systemic corticoids as judged by the investigator * current treatment with drugs known to have significant interference with glucose metabolism, such as systemic corticoids as judged by the investigator * presence of concomitant pathology such as heart failure, liver failure, kidney failure defined as egfr \<45ml/min * patient not able or willing to sign the patient informed consent

Keywords: exercise biomarker glucose lactate ketones continuous glucose monitoring
treatment of early childhood caries using silver diammine fluoride and sodium fluoride tricalciumphosphate and the effects on oral health related quality of life

Conditions: Early Childhood Caries; Dental Caries in Children; Dental Caries Extending Into Dentin; Dental Caries; Behavior, Child; Quality of Life

Summary: there is still a need for the assessment of different minimal intervention strategies and treatments focusing on the prevention and arrest of carious lesions of primary molars the evidence-based clinical practice guideline on non-restorative treatments for cavitated carious lesions advocate the use of silver diammine fluoride biannually for high caries risk patients

although sdf has been proven to be highly effective in carious lesion arrest and prevention, the staining effect, metallic taste due to silver content and the minimal mucosal irritation have been noted as primary cause of disinterest among clinicians in the use of this material. the use of naf-ftcp as a caries preventive material has not been studied widely. the importance of oral hygiene education and diet modification to achieve an effective caries control has been widely discussed. the off-label use of naf-ftcp as a caries arresting agent has not been studied on primary dentition. there is a dearth of evidence regarding the effectiveness of naf-ftcp towards caries arrest and prevention in pragmatic settings. a comparison between the sdf and naf-ftcp application on the cavitated carious primary molars and their effect on the oral health-related quality of life of the children has not been published in the literature.

Eligibility criteria:
inclusion criteria: children will be invited to participate in the trial if they fulfil the entire selection criteria as described below: * 4 to 6 years-of-age * identification of one or more carious primary molars without involvement of the pulp confirmed by bitewing radiographs * up to three teeth per each participant will be selected for intervention * has normal salivary flow rate * does not consume medications regularly for any medical condition * has not or will not receive any fluoride therapy or relevant dental therapy from other dental sources within the last six months exclusion criteria: children will be excluded from the trial if they fulfil any of the following criteria: * presence of any pain, ulceration, fistula/sinus or an abscess * premature hypermobility of carious teeth which can be potentially included in the study * history of allergy to any product containing silver compounds * siblings of the participants will not be allowed to participate to ensure any chance of ecohis duplication.

Keywords: sdf naf-ftcp child behavior pain experience wong-baker faces pain rating scale oral health-related quality of life caries arrest caries prevention silver diammine fluoride minimal intervention dentistry functionalized tricalcium phosphate sodium fluoride
microbiome and mycobiome registry of volunteers with and without autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: analyze, describe, and understand how the human gut microbiome (i.e. bacteriome and mycobiome) and autism spectrum disorder (asd) are related.


Eligibility criteria:
inclusion criteria: * volunteers \> 2 years of age * able to list all medical conditions and medications when applicable. * have already donated a stool sample to biohm™. exclusion criteria: * volunteers \< 2 years of age

Keywords: autism microbiome mycobiome bacteria fungi
requip rls post marketing surveillance

Conditions: Restless Legs Syndrome

Summary: post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for rls

this study is a post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for rls(restless leg syndrome) and identify saes, adverse drug reactions, and unexpected aes not described as precautions or warnings and to identify prognostic factors that have an effect on the aes and to assess effectiveness of ropinirole in real clinical practices after marketing. the subjects are patients prescribed for ropinirole by the investigators at the sites based on prescription information in normal clinical practices.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with rls by the investigator * subjects who the investigator believes that they can and will comply with the requirements of the protocol * to be contactable over the phone * to follow the administration regimen. * a male or female aged 18 years and more at the time of the first prescription. * subjects with no experience of rls treatment using ropinirole exclusion criteria: considering the nature of this non-interventional pms study, there is no strict exclusion criteria set up. gsk korea encourage the doctors participating this study to enrol the subjects prescribed with ropinirole following the locally approved prescribing information (appendix ) the following criteria should be checked at the time of study entry. * subjects with hypersensitivity to ropinirole and any excipients * female who is during the period of the pregnancy or who are lactating
comparative clinical and biochemical study evaluating the effectiveness of metformin versus febuxostat on gouty obese non-diabetic patients

Conditions: Gout

Summary: gout is a systemic disease that results from the deposition of monosodium urate crystals (msu) in tissues. increased serum uric acid (sua) above a specific threshold (\>6.8 mg/dl) is a requirement for the formation of uric acid crystals. msu crystals can be deposited in all tissues mainly in and around the joints forming tophi. early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (nsaids) or colchicine. lowering sua levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. this results in dissolution of msu crystals preventing further attacks


Eligibility criteria:
inclusion criteria: * males or females aged \< 18 years. * all patients are diagnosed to have gout with serum uric acid \< 7 mg/dl. * all patients are diagnosed to have obesity with body mass index (bmi) ≥ 30 kg/m2. exclusion criteria: * the presence of any type of diabetes mellitus. * patients with drug-induced hyperuriceamia (those taking anti-tb agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol). * non-obese patients with bmi \>30 kg/m2. * pregnant or lactating women.
relation of the area of cerclage with preterm birth

Conditions: Cervical Insufficiency

Summary: this study is planned prospectively in pregnancies who applied to etlik zübeyde hanım women's health care, training and research hospital which is a teritiary hospital with 15.000 births anually, between january 2022 and january 2023. cerclage treatment will be performed with the mcdonald technique (the type of cerclage suture will be mersilene) between the 16-23 weeks of gestation in pregnant women with a diagnosis of cervical insufficiency based on the history , physical examination or ultrasound findings according to acog. the investigators will measure cerclage area after cerclage treatment (within 0-4 weeks) and different parameters besides it by transvaginal ultrasound. it will be whether the collected data is related to the incidence of preterm birth.

the parameters that will be measured with transvaginal ultrasound are: * cerclage area in the axial plane of the cervix * angle between anterior uterine wall and internal os * angle between anterior uterine wall and external os * anterior and posterior cervical widht at level of stitch * anterior and posterior stitch depth (stitch to canal ) * cervical length above and below cerclage stitch before the data collection phase ,the required sample number for the research was determined using the g\*power (faul, erdfelder, buchner, \& lang, 2009) 3.1 program. when the alpha level is .05 and the power is %95 , the total number of samples was found o be 22.

Eligibility criteria:
inclusion criteria: * singleton pregnancy between 16-23 weeks of gestation and between the ages of 18-45 * according to acog based on history (having one or more painless abortions between 16-22 weeks of gestation , a history of cerclage * according to acog based on physical examination ( fetal membranes prolapsed from endocervical canal or not, cervical dilation present ) * accoding to acog based on ultrasound examination ( if there is no previous history of preterm birth , if the cervical length is 10mm or less, if the cervical length is less than 25mm with a history of preterm birth ) exclusion criteria: * multiple pregnancies * pregnant women with premature rupture of membranes * pregnant women with uterine anomalies * pregnant women with fetal anomalies * pregnant women with gestational diabetes mellitus, chronic or gestational hypertension , fetal growth restriction , oligohydroamnios or polihydroamnios

Keywords: cerclage area incidence of preterm birth mc donald